Taking on challenges of discovering therapeutics to address major unmet medical needs.
AiViva is a clinical stage biotech company founded in 2015 by four pharmaceutical industry veterans with more than 160 years of combined industry experience. AiViva's founders have demonstrated a successful track record across the full spectrum of drug development and commercialization, in addition to successful fundraises and IPOs on the NYSE and NASDAQ.
AiViva was formed with the mission of developing novel, innovative pharmaceutical products through an efficient, risk-mitigated development strategy to address major unmet medical needs.
We are developing drug products with the potential to transform treatment paradigms or significantly reduce the treatment burden for patients and physicians. Our approach leverages our proprietary JEL™ Technology to prolong the therapeutic effects of drugs and enhance their benefit-risk profiles. AiViva has a diverse pipeline of multiple novel drug candidates in development areas of dermatology, ophthalmology, oncology, and urology with the potential to expand to other areas of interest.
Areas of Focus
Dermatology
Ophthalmology
Urology
Oncology
JEL™ Technology
AiViva deploys an efficient, risk-mitigated development strategy that addresses diseases in specialty therapeutic areas where our innovative discoveries would provide a novel pharmacotherapy and/or reduce the treatment burden for both patients and physicians.
